Cognition Confirms FDA Alignment on Phase 3 Zervimesine Trial in DLB
CGTX sits 45% above its 52-week low of $0.55.
Summary
Cognition Therapeutics said the FDA agreed in writing on the key design elements of a pivotal Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies, including 100 mg once-daily dosing for nine months and NPI-2 as the primary endpoint. The company is now completing the protocol; no trial start date or cost was disclosed.
Key Events · Product Development and Regulatory · CGTX
-
FDA Aligns on Phase 3 Design
Written FDA feedback confirms alignment on patient selection, dose, duration and endpoints for a registrational Phase 3 study of zervimesine in dementia with Lewy bodies.
-
Trial Parameters Set
Mild-to-moderate DLB patients randomized to 100 mg once-daily oral zervimesine or placebo for nine months; primary endpoint is the NPI-2 hallucinations and delusions measure, with ADCS-ADL as key secondary.
-
Protocol Still Being Finalized
Cognition said it is completing a protocol to support the planned registrational study; no enrollment target, start date or budget was disclosed.
-
Funding Gap Remains
The last disclosed cash runway extended into Q4 2027 (August 10-Q), before Phase 3 costs were committed; the company has an existing $75M ATM program authorized in March 2026 that could fund the trial.
Analysis · CGTX · Life Sciences
The biggest regulatory design risk is now off the table before the trial starts: FDA written feedback locks in patient selection, 100 mg once-daily dosing, a nine-month duration, and NPI-2 hallucinations/delusions as the primary endpoint with ADCS-ADL as key secondary. That matters all the more in a disease with no approved treatments. Funding is the remaining hurdle, since the company must pay for a Phase 3 program and its last disclosed runway (into Q4 2027, per the August 10-Q) was set before this trial cost was committed. No start date, enrollment target, or cost estimate appears in the press release.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1560 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGTX was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $71M. The 52-week trading range was $0.55 to $1.93. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.